Publications
Detailed Information
Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cassese, Gianluca | - |
dc.contributor.author | Han, Ho Seong | - |
dc.contributor.author | Lee, Boram | - |
dc.contributor.author | Lee, Hae Won | - |
dc.contributor.author | Cho, Jai Young | - |
dc.contributor.author | Panaro, Fabrizio | - |
dc.contributor.author | Troisi, Roberto Ivan | - |
dc.date.accessioned | 2023-01-09T00:24:59Z | - |
dc.date.available | 2023-01-09T00:24:59Z | - |
dc.date.created | 2022-11-25 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | World Journal of Hepatology, Vol.14 No.10, pp.1862-1874 | - |
dc.identifier.issn | 1948-5182 | - |
dc.identifier.uri | https://hdl.handle.net/10371/188898 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and its incidence continues to increase. Despite improvements in both medical and surgical therapies, HCC remains associated with poor outcomes due to its high rates of recurrence and mortality. Approximately 50% of patients require systemic therapies that traditionally consist of tyrosine kinase inhibitors. Recently, however, immune checkpoint inhibitors have revolutionized HCC management, providing new therapeutic options. Despite these major advances, the different factors involved in poor clinical responses and molecular pathways leading to resistance following use of these therapies remain unclear. Alternative strategies, such as adoptive T cell transfer, vaccination, and virotherapy, are currently under evaluation. Combinations of immunotherapies with other systemic or local treatments are also being investigated and may be the most promising opportunities for HCC treatment. The aim of this review is to provide updated information on currently available immunotherapies for HCC as well as future perspectives. | - |
dc.language | 영어 | - |
dc.publisher | Baishideng Publishing Group | - |
dc.title | Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease | - |
dc.type | Article | - |
dc.identifier.doi | 10.4254/wjh.v14.i10.1862 | - |
dc.citation.journaltitle | World Journal of Hepatology | - |
dc.identifier.wosid | 000879068900002 | - |
dc.identifier.scopusid | 2-s2.0-85141764715 | - |
dc.citation.endpage | 1874 | - |
dc.citation.number | 10 | - |
dc.citation.startpage | 1862 | - |
dc.citation.volume | 14 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Han, Ho Seong | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.